0001209191-18-023744.txt : 20180404
0001209191-18-023744.hdr.sgml : 20180404
20180404165658
ACCESSION NUMBER: 0001209191-18-023744
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180402
FILED AS OF DATE: 20180404
DATE AS OF CHANGE: 20180404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LITALIEN JAMES J
CENTRAL INDEX KEY: 0001182613
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37693
FILM NUMBER: 18737937
MAIL ADDRESS:
STREET 1: C/O SOMAXON PHARMACEUTICALS, INC.
STREET 2: 3721 VALLEY CENTRE DRIVE, SUITE 500
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AveXis, Inc.
CENTRAL INDEX KEY: 0001652923
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 901038273
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
BUSINESS PHONE: 972-725-7797
MAIL ADDRESS:
STREET 1: 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-02
0
0001652923
AveXis, Inc.
AVXS
0001182613
LITALIEN JAMES J
C/O AVEXIS, INC.
2275 HALF DAY ROAD, SUITE 200
BANNOCKBURN
IL
60015
0
1
0
0
SrVP/Chief Reg&Quality Officer
Common Stock
2018-04-02
4
M
0
5000
18.17
A
8800
D
Common Stock
2018-04-02
4
S
0
1170
117.10
D
7630
D
Common Stock
2018-04-02
4
S
0
569
118.41
D
7061
D
Common Stock
2018-04-02
4
S
0
1297
119.43
D
5764
D
Common Stock
2018-04-02
4
S
0
1052
120.11
D
4712
D
Common Stock
2018-04-02
4
S
0
757
122.14
D
3955
D
Common Stock
2018-04-02
4
S
0
155
123.32
D
3800
D
Employee Stock Option (Right to Buy)
18.17
2018-04-02
4
M
0
5000
0.00
D
2025-08-11
Common Stock
5000
141800
D
These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on September 13, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.90 to $117.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.90 to $118.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.94 to $119.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.94 to $120.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.95 to $122.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.97 to $123.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.
37,950 shares vested and became exercisable on July 20, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until July 20, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date.
/s/Darren DeStefano, Attorney-in-Fact
2018-04-04